Which has preferable earnings & valuation, LIVN or ZBH?

Zimmer Biomet has higher revenue and earnings than LivaNova. Zimmer Biomet is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.21 -$242.47M $1.95 41.56 Zimmer Biomet $8.23B 2.14 $705.20M $3.85 23.60

Is LIVN or ZBH more profitable?

Zimmer Biomet has a net margin of 9.05% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Zimmer Biomet's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% Zimmer Biomet 9.05% 13.24% 7.28%

Does the media refer more to LIVN or ZBH?

In the previous week, Zimmer Biomet had 3 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for Zimmer Biomet and 2 mentions for LivaNova. Zimmer Biomet's average media sentiment score of 1.15 beat LivaNova's score of 0.89 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, SOLV or LIVN?

Solventum has higher revenue and earnings than LivaNova. Solventum is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.33B 1.62 $1.56B $8.16 9.54 LivaNova $1.39B 3.21 -$242.47M $1.95 41.56

Is SOLV or LIVN more profitable?

Solventum has a net margin of 17.33% compared to LivaNova's net margin of 7.48%. Solventum's return on equity of 23.51% beat LivaNova's return on equity. Company Net Margins Return on Equity Return on Assets Solventum 17.33% 23.51% 7.63% LivaNova 7.48% 16.48% 7.59%

Does the media prefer SOLV or LIVN?

In the previous week, Solventum had 1 more articles in the media than LivaNova. MarketBeat recorded 3 mentions for Solventum and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.89 beat Solventum's score of 0.25 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LivaNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, SNN or LIVN?

Smith & Nephew SNATS has higher revenue and earnings than LivaNova. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.08 $625M N/A N/A LivaNova $1.39B 3.21 -$242.47M $1.95 41.56

Does the media prefer SNN or LIVN?

In the previous week, LivaNova had 1 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 2 mentions for LivaNova and 1 mentions for Smith & Nephew SNATS. LivaNova's average media sentiment score of 0.89 beat Smith & Nephew SNATS's score of 0.00 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LivaNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, PEN or LIVN?

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.40B 8.90 $177.69M $4.34 73.19 LivaNova $1.39B 3.21 -$242.47M $1.95 41.56

Is PEN or LIVN more profitable?

Penumbra has a net margin of 11.76% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 11.76% 10.87% 8.45% LivaNova 7.48% 16.48% 7.59%

Does the media prefer PEN or LIVN?

In the previous week, LivaNova had 1 more articles in the media than Penumbra. MarketBeat recorded 2 mentions for LivaNova and 1 mentions for Penumbra. LivaNova's average media sentiment score of 0.89 beat Penumbra's score of 0.57 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, GKOS or LIVN?

Glaukos has higher earnings, but lower revenue than LivaNova. Glaukos is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 16.44 -$187.69M -$3.28 N/A LivaNova $1.39B 3.21 -$242.47M $1.95 41.56

Is GKOS or LIVN more profitable?

LivaNova has a net margin of 7.48% compared to Glaukos' net margin of -34.34%. LivaNova's return on equity of 16.48% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% LivaNova 7.48% 16.48% 7.59%

Does the media prefer GKOS or LIVN?

In the previous week, Glaukos had 3 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for Glaukos and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.89 beat Glaukos' score of 0.87 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

LivaNova (LIVN) Competitors

$81.05 +1.10 (+1.38%)

Closing price 04:00 PM Eastern

Extended Trading

$80.96 -0.09 (-0.11%)

As of 04:10 PM Eastern

Compare

LIVN vs. ZBH, SOLV, SNN, PEN, and GKOS

Should you buy LivaNova stock or one of its competitors? MarketBeat compares LivaNova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LivaNova include Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), Penumbra (PEN), and Glaukos (GKOS). These companies are all part of the "medical equipment" industry.

How does LivaNova compare to Zimmer Biomet?

LivaNova (NASDAQ:LIVN) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

In the previous week, Zimmer Biomet had 3 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for Zimmer Biomet and 2 mentions for LivaNova. Zimmer Biomet's average media sentiment score of 1.15 beat LivaNova's score of 0.89 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zimmer Biomet has a net margin of 9.05% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Zimmer Biomet	9.05%	13.24%	7.28%

97.6% of LivaNova shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zimmer Biomet has higher revenue and earnings than LivaNova. Zimmer Biomet is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.21	-$242.47M	$1.95	41.56
Zimmer Biomet	$8.23B	2.14	$705.20M	$3.85	23.60

LivaNova has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

LivaNova presently has a consensus price target of $80.75, indicating a potential downside of 0.37%. Zimmer Biomet has a consensus price target of $102.70, indicating a potential upside of 13.02%. Given Zimmer Biomet's higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

Summary

Zimmer Biomet beats LivaNova on 10 of the 17 factors compared between the two stocks.

How does LivaNova compare to Solventum?

Solventum (NYSE:SOLV) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Solventum currently has a consensus target price of $84.25, indicating a potential upside of 8.25%. LivaNova has a consensus target price of $80.75, indicating a potential downside of 0.37%. Given Solventum's higher possible upside, equities research analysts plainly believe Solventum is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

97.6% of LivaNova shares are held by institutional investors. 0.2% of Solventum shares are held by company insiders. Comparatively, 0.4% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Solventum has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Solventum has higher revenue and earnings than LivaNova. Solventum is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.62	$1.56B	$8.16	9.54
LivaNova	$1.39B	3.21	-$242.47M	$1.95	41.56

In the previous week, Solventum had 1 more articles in the media than LivaNova. MarketBeat recorded 3 mentions for Solventum and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.89 beat Solventum's score of 0.25 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has a net margin of 17.33% compared to LivaNova's net margin of 7.48%. Solventum's return on equity of 23.51% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
LivaNova	7.48%	16.48%	7.59%

Summary

Solventum beats LivaNova on 9 of the 16 factors compared between the two stocks.

How does LivaNova compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Smith & Nephew SNATS has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

Smith & Nephew SNATS currently has a consensus price target of $30.93, indicating a potential upside of 2.32%. LivaNova has a consensus price target of $80.75, indicating a potential downside of 0.37%. Given Smith & Nephew SNATS's higher possible upside, research analysts clearly believe Smith & Nephew SNATS is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Smith & Nephew SNATS has higher revenue and earnings than LivaNova.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.08	$625M	N/A	N/A
LivaNova	$1.39B	3.21	-$242.47M	$1.95	41.56

In the previous week, LivaNova had 1 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 2 mentions for LivaNova and 1 mentions for Smith & Nephew SNATS. LivaNova's average media sentiment score of 0.89 beat Smith & Nephew SNATS's score of 0.00 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has a net margin of 7.48% compared to Smith & Nephew SNATS's net margin of 0.00%. LivaNova's return on equity of 16.48% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
LivaNova	7.48%	16.48%	7.59%

Summary

LivaNova beats Smith & Nephew SNATS on 10 of the 14 factors compared between the two stocks.

How does LivaNova compare to Penumbra?

Penumbra (NYSE:PEN) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Penumbra presently has a consensus target price of $361.33, indicating a potential upside of 13.75%. LivaNova has a consensus target price of $80.75, indicating a potential downside of 0.37%. Given Penumbra's higher probable upside, analysts plainly believe Penumbra is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.90	$177.69M	$4.34	73.19
LivaNova	$1.39B	3.21	-$242.47M	$1.95	41.56

In the previous week, LivaNova had 1 more articles in the media than Penumbra. MarketBeat recorded 2 mentions for LivaNova and 1 mentions for Penumbra. LivaNova's average media sentiment score of 0.89 beat Penumbra's score of 0.57 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Penumbra has a net margin of 11.76% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.76%	10.87%	8.45%
LivaNova	7.48%	16.48%	7.59%

Penumbra has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

88.9% of Penumbra shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 2.9% of Penumbra shares are held by company insiders. Comparatively, 0.4% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Penumbra beats LivaNova on 9 of the 16 factors compared between the two stocks.

How does LivaNova compare to Glaukos?

Glaukos (NYSE:GKOS) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, Glaukos had 3 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for Glaukos and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.89 beat Glaukos' score of 0.87 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos has higher earnings, but lower revenue than LivaNova. Glaukos is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	16.44	-$187.69M	-$3.28	N/A
LivaNova	$1.39B	3.21	-$242.47M	$1.95	41.56

LivaNova has a net margin of 7.48% compared to Glaukos' net margin of -34.34%. LivaNova's return on equity of 16.48% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
LivaNova	7.48%	16.48%	7.59%

Glaukos presently has a consensus target price of $149.17, indicating a potential upside of 5.02%. LivaNova has a consensus target price of $80.75, indicating a potential downside of 0.37%. Given Glaukos' stronger consensus rating and higher possible upside, analysts plainly believe Glaukos is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Glaukos has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 0.4% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Glaukos and LivaNova tied by winning 8 of the 16 factors compared between the two stocks.

Get LivaNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIVN vs. The Competition

Export

Metric	LivaNova	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.39B	$7.27B	$6.61B	$12.27B
Dividend Yield	N/A	1.26%	2.67%	5.87%
P/E Ratio	41.56	49.62	26.02	23.97
Price / Sales	3.21	79.43	542.89	101.47
Price / Cash	16.53	25.66	46.33	53.91
Price / Book	3.69	7.40	10.51	6.32
Net Income	-$242.47M	$159.20M	$3.57B	$337.22M
7 Day Performance	3.25%	0.88%	0.81%	-1.20%
1 Month Performance	9.78%	0.51%	0.68%	0.40%
1 Year Performance	76.70%	7.06%	30.98%	29.26%

LivaNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIVN LivaNova	2.1765 of 5 stars	$81.05 +1.4%	$80.75 -0.4%	+73.7%	$4.39B	$1.39B	41.56	3,300	Analyst Forecast
ZBH Zimmer Biomet	4.023 of 5 stars	$87.29 -0.8%	$102.70 +17.7%	-2.0%	$17.02B	$8.41B	22.67	17,000	Positive News
SOLV Solventum	3.532 of 5 stars	$73.41 -2.7%	$84.25 +14.8%	+0.8%	$13.06B	$8.33B	9.00	20,000
SNN Smith & Nephew SNATS	1.9332 of 5 stars	$29.38 -2.3%	$30.93 +5.3%	+1.4%	$12.79B	$6.16B	N/A	16,988	News Coverage
PEN Penumbra	2.3488 of 5 stars	$316.49 -0.2%	$361.33 +14.2%	+23.8%	$12.48B	$1.40B	72.92	4,700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIVN) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LivaNova (LIVN) Competitors

LIVN vs. ZBH, SOLV, SNN, PEN, and GKOS

How does LivaNova compare to Zimmer Biomet?

Summary

How does LivaNova compare to Solventum?

Summary

How does LivaNova compare to Smith & Nephew SNATS?

Summary

How does LivaNova compare to Penumbra?

Summary

How does LivaNova compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIVN vs. The Competition

LivaNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LivaNova (LIVN) Competitors

LIVN vs. ZBH, SOLV, SNN, PEN, and GKOS

How does LivaNova compare to Zimmer Biomet?

Does the media refer more to LIVN or ZBH?

Is LIVN or ZBH more profitable?

Do institutionals and insiders believe in LIVN or ZBH?

Which has preferable earnings & valuation, LIVN or ZBH?

Which has more volatility and risk, LIVN or ZBH?

Do analysts prefer LIVN or ZBH?

Summary

How does LivaNova compare to Solventum?

Do analysts rate SOLV or LIVN?

Do institutionals & insiders believe in SOLV or LIVN?

Which has more risk & volatility, SOLV or LIVN?

Which has stronger earnings and valuation, SOLV or LIVN?

Does the media prefer SOLV or LIVN?

Is SOLV or LIVN more profitable?

Summary

How does LivaNova compare to Smith & Nephew SNATS?

Which has more risk and volatility, SNN or LIVN?

Do analysts rate SNN or LIVN?

Do insiders & institutionals believe in SNN or LIVN?

Which has better valuation and earnings, SNN or LIVN?

Does the media prefer SNN or LIVN?

Is SNN or LIVN more profitable?

Summary

How does LivaNova compare to Penumbra?

Do analysts rate PEN or LIVN?

Which has preferable earnings & valuation, PEN or LIVN?

Does the media prefer PEN or LIVN?

Is PEN or LIVN more profitable?

Which has more volatility and risk, PEN or LIVN?

Do insiders and institutionals believe in PEN or LIVN?

Summary

How does LivaNova compare to Glaukos?

Does the media prefer GKOS or LIVN?

Which has preferable valuation and earnings, GKOS or LIVN?

Is GKOS or LIVN more profitable?

Do analysts prefer GKOS or LIVN?

Which has more volatility and risk, GKOS or LIVN?

Do institutionals & insiders believe in GKOS or LIVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIVN vs. The Competition

LivaNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools